Site search
2831 results for '' found
Hearts and Minds: A 3-arm Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Metformin and Atorvastatin for the Treatment of Depression and Medical Comorbidity (ACTRN1262300061162
Hearts and Minds: A 3-arm Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Metformin and Atorvastatin for the Treatment of Depression and Medical Comorbidity (ACTRN1262300061162
/
Efficacy and Safety of HB-1 for Panic Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (NCT05071430)
Efficacy and Safety of HB-1 for Panic Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (NCT05071430)
/
Evaluation of safety and performance of the Half Moon Transcatheter Mitral Valve Repair (TMVr) System in High Risk Patients with Severe Symptomatic Mitral Regurgitation. (ACTRN04343313)
Evaluation of safety and performance of the Half Moon Transcatheter Mitral Valve Repair (TMVr) System in High Risk Patients with Severe Symptomatic Mitral Regurgitation. (ACTRN04343313)
/
HALEO - A phase 3, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of NTLA-2002 in participants with hereditary angioedema [HAE] (NCT06634420
HALEO - A phase 3, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of NTLA-2002 in participants with hereditary angioedema [HAE] (NCT06634420
/
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis (HABOR) (NCT04910685)
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis (HABOR) (NCT04910685)
/
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced
/
GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (NCT04854499)
GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (NCT04854499)
/
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies (NCT04778410)
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies (NCT04778410)
/
A Phase 2 Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults (NCT05729568)
A Phase 2 Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults (NCT05729568)
/
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (NCT05
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (NCT05
/